Verrica Pharmaceuticals' Chief Legal Officer Christopher Hayes resigns effective April 30, 2025

Verrica Pharmaceuticals Inc.

Christopher G. Hayes resigns as Chief Legal Officer, Chief Compliance Officer, and Corporate Secretary effective April 30, 2025.
Company enters Release Agreement providing 12 months of base salary continuation and up to 12 months of COBRA coverage.
No permanent replacement has been announced for Hayes' roles.

item 5.02 item 9.01

Executive movements

Machine-extracted from this filing. Every card cites the SEC source. See all recent executive movements.

Departed

Christopher G. Hayes

Chief Legal Officer, Chief Compliance Officer and Corporate Secretary

VRCA · Verrica Pharmaceuticals Inc.

Effective: 2025-04-30
Filed: April 25, 2025, 7:59 PM ET

On April 22, 2025, Christopher G. Hayes notified Verrica Pharmaceuticals Inc. (the “ Company ”) that he will resign from his positions as the Company’s Chief Legal Officer, Chief Compliance Officer and Corporate Secretary effective as of April 30, 2025

Key facts

Extracted from this filing and checked against the source text.

Executive change SEC 8-K Item 5.02 confidence 0.95

Christopher G. Hayes departed as Chief Legal Officer, Chief Compliance Officer and Corporate Secretary at Verrica Pharmaceuticals Inc..

Action: resign
Role: Chief Legal Officer, Chief Compliance Officer and Corporate Secretary

Exact text from the filing

On April 22, 2025, Christopher G. Hayes notified Verrica Pharmaceuticals Inc. (the “ Company ”) that he will resign from his positions as the Company’s Chief Legal Officer, Chief Compliance Officer and Corporate Secretary effective as of April 30, 2025

View on SEC.gov

Verrica Pharmaceuticals Inc. filing history →

Source: SEC EDGAR

accession 0001193125-25-096909

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.